Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06798012 · ClinicalTrials.gov registry record · Phase 2

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

A Phase 2 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), sponsored by Takeda.

Recruiting
Registry status
Phase 2
Development phase
36
Enrollment target
20
Study locations

NCT06798012 is a Phase 2 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) that is actively recruiting participants, run by Takeda. The registered enrollment target is 36 participants, below the 41-participant average among 3 other Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06798012, a Phase 2 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), is actively recruiting participants, sponsored by Takeda.

RECRUITING
Registry status
Phase 2
Development phase
36 participants
Enrollment target
20
Study locations

Study Summary

CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG). TAK-411 is a special type of immune globulin G (hsIgG) that has been chemically changed. It is made from IG that comes from human plasma. This study will test if TAK-411 can decrease inflammation and improve symptoms of CIDP. The main aim of this study is to check how TAK-411 affects the physical functioning of adults with CIDP when compared with results of the placebo group of a historical trial. Participants may be treated with TAK-411 for up to 1 year (51 weeks) and will be followed up for 3 weeks after last dose. During the study, participants may visit their study clinic up to approximately 21 times.

Conditions Studied

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Interventions

  • BIOLOGICAL TAK-411

Study Locations (20)

Florida

  • UF Health Neurology - Jacksonville - Jacksonville
  • Visionary Investigators Network - Miami
  • University of South Florida - Tampa

California

  • University of California San Diego - La Jolla
  • California Pacific Medical Center - San Francisco

Missouri

  • The Curators of the University of Missouri on behalf of University of Missouri Health Care - Columbia
  • The Washington University - St Louis

Other

  • Universidad del Rosario - Bogotá
  • Fundacion Oftalmologica de Santander - FOSCAL - Bucaramanga

Georgia

  • Emory University - Atlanta

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Minnesota

  • Mayo Clinic Rochester - Rochester

Pennsylvania

  • Penn Blood Disorders Program - Hospital of The University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2025-05-14
Est. Completion 2028-06-08
Phase Phase 2

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06798012

The ClinicalTrials.gov registry entry for NCT06798012 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 41-participant average among 3 other Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trials with a reported enrollment target (12% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) appearing as the primary indexed condition, and to 1 intervention - of which TAK-411 is the first listed.

NCT06798012 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, California, Missouri.

Frequently Asked Questions

What is clinical trial NCT06798012 about?

NCT06798012 is a clinical study titled "A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)". CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to mus...

What is the current status of trial NCT06798012?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2025-05-14. Estimated completion is 2028-06-08.

What conditions does trial NCT06798012 study?

This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

What interventions are being tested in trial NCT06798012?

The interventions under investigation include: TAK-411 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06798012?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06798012 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.